Phenytoin possesses a relatively small therapeutic index, and toxicity is by no means uncommon during therapy making monitoring of plasma levels an important adjunct to clinical management (Dawson and Jamieson, 1971). This situation is further complicated by the non-linear relationship between dose and the resulting plasma concentration (Bochner et al., 1972) . The apparent half-life of the drug increases as the plasma level rises, phenytoin elimination being described as dose-dependent. This type of elimination can be described as obeying Michaelis-Menten kinetics overall (Gerber and Wagner, 1972) . It follows from these kinetic properties that the relationship of plasma levels to dose is non-linear, and that at higher plasma levels a small increase in dose produces a disproportionately large increase in plasma levels. The 
SUM MAR Y Phenytoin elimination is a saturable process obeying Michaelis-Menten kinetics. Plasma phenytoin levels are not related linearly to dose, and small changes in enzyme activity produced by concurrent drug therapy could alter plasma levels. Two cases of phenytoin intoxication associated with simultaneous administration of diazepam are reported. Intravenous phenytoin infusions were given and the apparent Km and Vmax computed from the resulting plasma phenytoin levels. In one case 'Km' and 'Vnax' were 0.8 ytmol/l and 1.3 ,tmol/l/hour respectively during concurrent diazepam administration, and 50.3 ,umol/l and 4.4 ,tmol/l/hour after discontinuation of diazepam. In the second case phenytoin infusion with diazepam gave 'Km' and 'Vm.X' values of 0.012 ymol/I and 0.95 ,umol/l/hour. Without diazepam these were 28.8 umol/l and 0.92 yumol/l/hour respectively.
Phenytoin possesses a relatively small therapeutic index, and toxicity is by no means uncommon during therapy making monitoring of plasma levels an important adjunct to clinical management (Dawson and Jamieson, 1971) . This situation is further complicated by the non-linear relationship between dose and the resulting plasma concentration (Bochner et al., 1972) . The apparent half-life of the drug increases as the plasma level rises, phenytoin elimination being described as dose-dependent. This type of elimination can be described as obeying Michaelis-Menten kinetics overall (Gerber and Wagner, 1972) . It follows from these kinetic properties that the relationship of plasma levels to dose is non-linear, and that at higher plasma levels a small increase in dose produces a disproportionately large increase in plasma levels. The (Gerber and Wagner, 1972) and may be characterised by an apparent Km ('Ki') and an apparent Vmax ('Vmax'). The parameters 'Km', and 'Vm..' were varied to obtain the best fit (by a least squares method) of the calculated curve to the observed data.
Results
The data for intravenous phenytoin infusion with and without concurrent diazepam administration in patient 1 are plotted on semilogarithmic coordinates in Fig. 1 In the absence of diazepam, the calculated 'K,1.' is in the same range as the plasma phenytoin concentration. Under such conditions the configuration and position of the elimination curve are largely determined by the value of 'K.. ' 
Discussion
The toxicity observed in these two patients includes the clinical features of nystagmus, ataxia, dysarthria, lethargy, and inability to concentrate which have been shown to be related to plasma phenytoin levels (Kutt et al., 1964) . As in previously reported cases, the toxicity was reversible with reduction of the plasma phenytoin concentration.
Interaction between benzodiazepines and phenytoin is not well-documented. Chlordiazepoxide has been cited as a cause of elevated phenytoin plasma levels (Kutt and McDowell, 1968) . Kariks et al. (1971) state that in a group of institutionalised epileptic patients treated with phenytoin those receiving diazepam in addition may have higher plasma phenytoin levels. In a report by Shuttleworth et al. (1974) concerned with choreoathetosis and phenytoin intoxication, one of the three cases discussed (case 2) developed choreoathetosis associated with raised plasma phenytoin levels while being treated with diazepam. Details were not given on the temporal relationship of toxicity to diazepam administration but toxicity did not reappear when this patient was restarted on phenytoin alone. This patient's illness was attributed to voluntary overdosage but might also be explained by a drug interaction. The best documented evidence of an interaction between diazepam and phenytoin comes from the study of Vajda et al. (1971) in which phenytoin was given to evaluate its effect as an anti-arrhythmic agent after myocardial infarction. Some patients also received chlordiazepoxide or diazepam, and in all five cases where phenytoin plasma levels were available before and after benzodiazepine administration, these levels were markedly increased after benzodiazepine therapy. Furthermore, in a large group of patients it was found that mean plasma phenytoin levels were significantly higher if benzodiazepines were simultaneously given with phenytoin. Houghton and Richens (1974) , on the other hand, found a small but significant fall in serum phenytoin levels when benzodiazepines were given. This was associated with a reduced phenytoin half-life and a change in the ratio of 5-p-hydroxyphenyl-5-phenylhydantoin to phenytoin in favour of the metabolite. They suggested that benzodiazepines act as weak inducing agents in this situation.
The mechanism for the apparent saturation of the system for phenytoin elimination seen in our cases is unknown but saturation of the enzyme catalysing phenytoin hydroxylation is a possibility. Studies on phenytoin metabolism by rat liver microsomes in vitro by Kutt and Verebely (1970) showed the drug to be metabolised by an enzymic process obeying Michaelis-Menten kinetics, the rate-limiting step being parahydroxylation to 5-p-hydroxyphenyl-5-phenylhydantoin. Measurement of the apparent Km for this process gave a mean value of 37.3 ,tmol/l. In our patients, in the absence of diazepam, the 'Km' was 50.3 ,umol/l in patient 1 and 28.8 ,umol/l in patient 2. Although the correlation of an apparent Km estimated using isolated organelles with a 'Ki' determined from patient data must be viewed with caution, these values are of the same order of magnitude. The parameters calculated for our patients may be compared with a 'Km' of 26.8 iumol/1 and a 'Vmax' of 1 ytmol/l/hour determined by Gerber and Wagner (1972) for a single subject and with the mean values of a 'Km' of 15.1 ptmol/l and 'Vmax' 1.36 pmol/l/hour determined by Mawer et al. (1974) from 15 patients. Kutt and Verebely (1970) found that diazepam inhibited phenytoin metabolism by rat liver microsomes in vitro. With 10-3 M diazepam 91% inhibition occurred, and 32% inhibition with 10-4 M, but the type of inhibition was undetermined. During diazepam therapy the plateau plasma levels are of the order of 0.7 ,Lmol/l (Kaplan et al. 1973) The data from case 2, even in the absence of diazepam, suggest that this patient had a slow rate of phenytoin elimination (Kutt, 1971) . This may have put him at special risk for phenytoin toxicity when diazepam was added to his antiepileptic drug therapy. That prolonged elevations of plasma phenytoin level may occur is illustrated by this patient whose phenytoin levels remained raised for several days after withdrawal of oral phenytoin during which time he remained toxic. The descending limb of this curve provided the second estimate for 'Km1' and 'Vm.x' in the Table.
We conclude that the interaction between diazepam and phenytoin is of clinical significance although its prevalence has yet to be determined. The report of Vajda et al. (1971) suggests that it could be relatively common, although the work of Houghton and Richens (1974) indicates that not all patients may respond in the same way to this drug combination. Probably a similar interaction may apply to other benzodiazepines, and with increasing use of these compounds as adjuncts in the control of epilepsy this interaction may be of increasing importance in the future.
